Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1985 1
1986 2
1987 5
1988 1
1989 3
1990 2
1991 3
1992 7
1993 5
1994 8
1995 16
1996 12
1997 20
1998 19
1999 38
2000 61
2001 62
2002 69
2003 100
2004 139
2005 161
2006 213
2007 237
2008 299
2009 384
2010 433
2011 461
2012 571
2013 599
2014 646
2015 706
2016 659
2017 773
2018 826
2019 859
2020 924
2021 981
2022 943
2023 861
2024 298

Text availability

Article attribute

Article type

Publication date

Search Results

10,960 results

Results by year

Filters applied: . Clear all
Page 1
Elucidating the mechanisms of Temozolomide resistance in gliomas and the strategies to overcome the resistance.
Tomar MS, Kumar A, Srivastava C, Shrivastava A. Tomar MS, et al. Biochim Biophys Acta Rev Cancer. 2021 Dec;1876(2):188616. doi: 10.1016/j.bbcan.2021.188616. Epub 2021 Aug 20. Biochim Biophys Acta Rev Cancer. 2021. PMID: 34419533 Review.
Temozolomide (TMZ) is a first-choice alkylating agent inducted as a gold standard therapy for glioblastoma multiforme (GBM) and astrocytoma. ...
Temozolomide (TMZ) is a first-choice alkylating agent inducted as a gold standard therapy for glioblastoma multiforme (GBM) and astro …
Potential Strategies Overcoming the Temozolomide Resistance for Glioblastoma.
Jiapaer S, Furuta T, Tanaka S, Kitabayashi T, Nakada M. Jiapaer S, et al. Neurol Med Chir (Tokyo). 2018 Oct 15;58(10):405-421. doi: 10.2176/nmc.ra.2018-0141. Epub 2018 Sep 21. Neurol Med Chir (Tokyo). 2018. PMID: 30249919 Free PMC article. Review.
Although the current standard therapy consists of surgery followed by radiation and temozolomide (TMZ), chemotherapy can extend patient's post-operative survival but most cases eventually demonstrate resistance to TMZ. ...
Although the current standard therapy consists of surgery followed by radiation and temozolomide (TMZ), chemotherapy can extend patie …
Randomized Phase II Trial of Vincristine-Irinotecan With or Without Temozolomide, in Children and Adults With Relapsed or Refractory Rhabdomyosarcoma: A European Paediatric Soft Tissue Sarcoma Study Group and Innovative Therapies for Children With Cancer Trial.
Defachelles AS, Bogart E, Casanova M, Merks JHM, Bisogno G, Calareso G, Gallego Melcon S, Gatz SA, Le Deley MC, McHugh K, Probst A, Rocourt N, van Rijn RR, Wheatley K, Minard-Colin V, Chisholm JC. Defachelles AS, et al. J Clin Oncol. 2021 Sep 20;39(27):2979-2990. doi: 10.1200/JCO.21.00124. Epub 2021 Aug 3. J Clin Oncol. 2021. PMID: 34343032 Clinical Trial.
PURPOSE: The VIT-0910 trial was conducted to evaluate efficacy and safety of the vincristine-irinotecan combination with and without temozolomide (VIT and VI, respectively) in relapsed or refractory rhabdomyosarcoma (RMS). ...Overall, patients experienced adverse events gr …
PURPOSE: The VIT-0910 trial was conducted to evaluate efficacy and safety of the vincristine-irinotecan combination with and without temo …
Recent Advances in the Therapeutic Strategies of Glioblastoma Multiforme.
Aldoghachi AF, Aldoghachi AF, Breyne K, Ling KH, Cheah PS. Aldoghachi AF, et al. Neuroscience. 2022 May 21;491:240-270. doi: 10.1016/j.neuroscience.2022.03.030. Epub 2022 Apr 6. Neuroscience. 2022. PMID: 35395355 Review.
At present, the standard of care includes surgical tumor resection, followed by radiation therapy concomitant with chemotherapy and temozolomide. New developments and significant advances in the treatment of GBM have been achieved in recent decades. ...
At present, the standard of care includes surgical tumor resection, followed by radiation therapy concomitant with chemotherapy and temoz …
PTRF/Cavin-1 enhances chemo-resistance and promotes temozolomide efflux through extracellular vesicles in glioblastoma.
Yang E, Wang L, Jin W, Liu X, Wang Q, Wu Y, Tan Y, Wang Y, Cui X, Zhao J, Tong F, Hong B, Xiao M, Liu X, Fang C, Kang C. Yang E, et al. Theranostics. 2022 May 16;12(9):4330-4347. doi: 10.7150/thno.71763. eCollection 2022. Theranostics. 2022. PMID: 35673568 Free PMC article.
The high expression of polymerase I and transcript release factor (PTRF) is correlated with a worse prognosis in glioma patients. However, the importance of PTRF on temozolomide (TMZ) resistance in glioblastoma (GBM) is poorly understood. ...
The high expression of polymerase I and transcript release factor (PTRF) is correlated with a worse prognosis in glioma patients. However, t …
Pericytes augment glioblastoma cell resistance to temozolomide through CCL5-CCR5 paracrine signaling.
Zhang XN, Yang KD, Chen C, He ZC, Wang QH, Feng H, Lv SQ, Wang Y, Mao M, Liu Q, Tan YY, Wang WY, Li TR, Che LR, Qin ZY, Wu LX, Luo M, Luo CH, Liu YQ, Yin W, Wang C, Guo HT, Li QR, Wang B, Chen W, Wang S, Shi Y, Bian XW, Ping YF. Zhang XN, et al. Cell Res. 2021 Oct;31(10):1072-1087. doi: 10.1038/s41422-021-00528-3. Epub 2021 Jul 8. Cell Res. 2021. PMID: 34239070 Free PMC article.
Herein, we uncovered that pericytes potentiate DNA damage repair (DDR) in GBM cells residing in the perivascular niche, which induces temozolomide (TMZ) chemoresistance. We found that increased pericyte proportion correlates with accelerated tumor recurrence and worse prog …
Herein, we uncovered that pericytes potentiate DNA damage repair (DDR) in GBM cells residing in the perivascular niche, which induces tem …
Antitumor Activity of a Mitochondrial-Targeted HSP90 Inhibitor in Gliomas.
Wei S, Yin D, Yu S, Lin X, Savani MR, Du K, Ku Y, Wu D, Li S, Liu H, Tian M, Chen Y, Bowie M, Hariharan S, Waitkus M, Keir ST, Sugarman ET, Deek RA, Labrie M, Khasraw M, Lu Y, Mills GB, Herlyn M, Wu K, Liu L, Wei Z, Flaherty KT, Abdullah K, Zhang G, Ashley DM. Wei S, et al. Clin Cancer Res. 2022 May 13;28(10):2180-2195. doi: 10.1158/1078-0432.CCR-21-0833. Clin Cancer Res. 2022. PMID: 35247901 Free PMC article.
PURPOSE: To investigate the antitumor activity of a mitochondrial-localized HSP90 inhibitor, Gamitrinib, in multiple glioma models, and to elucidate the antitumor mechanisms of Gamitrinib in gliomas. EXPERIMENTAL DESIGN: A broad panel of primary and temozolomide (TMZ)-resi …
PURPOSE: To investigate the antitumor activity of a mitochondrial-localized HSP90 inhibitor, Gamitrinib, in multiple glioma models, and to e …
Lysine methylation promotes NFAT5 activation and determines temozolomide efficacy in glioblastoma.
Li Y, Gao Z, Wang Y, Pang B, Zhang B, Hu R, Wang Y, Liu C, Zhang X, Yang J, Mei M, Wang Y, Zhou X, Li M, Ren Y. Li Y, et al. Nat Commun. 2023 Jul 10;14(1):4062. doi: 10.1038/s41467-023-39845-z. Nat Commun. 2023. PMID: 37429858 Free PMC article.
Temozolomide (TMZ) therapy offers minimal clinical benefits in patients with glioblastoma multiforme (GBM) with high EGFR activity, underscoring the need for effective combination therapy. ...
Temozolomide (TMZ) therapy offers minimal clinical benefits in patients with glioblastoma multiforme (GBM) with high EGFR activity, u …
Brain Co-Delivery of Temozolomide and Cisplatin for Combinatorial Glioblastoma Chemotherapy.
Zou Y, Wang Y, Xu S, Liu Y, Yin J, Lovejoy DB, Zheng M, Liang XJ, Park JB, Efremov YM, Ulasov I, Shi B. Zou Y, et al. Adv Mater. 2022 Aug;34(33):e2203958. doi: 10.1002/adma.202203958. Epub 2022 Jul 17. Adv Mater. 2022. PMID: 35738390
Glioblastoma (GBM) is an intractable malignancy with high recurrence and mortality. Combinatorial therapy based on temozolomide (TMZ) and cisplatin (CDDP) shows promising potential for GBM therapy in clinical trials. ...
Glioblastoma (GBM) is an intractable malignancy with high recurrence and mortality. Combinatorial therapy based on temozolomide (TMZ) …
Brain-Targeted HFn-Cu-REGO Nanoplatform for Site-Specific Delivery and Manipulation of Autophagy and Cuproptosis in Glioblastoma.
Jia W, Tian H, Jiang J, Zhou L, Li L, Luo M, Ding N, Nice EC, Huang C, Zhang H. Jia W, et al. Small. 2023 Jan;19(2):e2205354. doi: 10.1002/smll.202205354. Epub 2022 Nov 18. Small. 2023. PMID: 36399643
Durable glioblastoma multiforme (GBM) management requires long-term chemotherapy after surgery to eliminate remaining cancerous tissues. Among chemotherapeutics, temozolomide is considered as the first-line drug for GBM therapy, but the treatment outcome is not satisfactor …
Durable glioblastoma multiforme (GBM) management requires long-term chemotherapy after surgery to eliminate remaining cancerous tissues. Amo …
10,960 results
You have reached the last available page of results. Please see the User Guide for more information.